OBJECTIVES: to reveal the trends in prices and consumption of antineoplastic medicines used for solid tumors treatment after the market authorization of their generic or biosimilar copies in Russia.

METHODS:Based on a patent search and Russian state register of medicines we found the international non-patent names (INN) of antineoplastic drugs with the generic or biosimilar copies that received market authorization in Russia in 2010-2018. Drugs used for solid tumors treatment were selected. Data on their prices and state procurement volumes were extracted from the government procurement information system. Growth rates were calculated for prices and consumption of drugs whose copies circulated in the market for at least 4 years and market share of branded drugs and their copies was assessed.

RESULTS: 8 generic or biosimilar drugs for solid tumors treatment received market authorization in Russia in 2010-2018. Prices were steadily decreasing both for most branded drugs and their copies after the authorization of a generic or biosimilar but there were great differences between individual drugs. The prices growth rates varied from -50% to + 22% for branded medicines and from -35% to -69% for generics/biosimilars. Consumption was increased for all INN with a range of +30% to +548%. The market share of original drugs decreased from 100% to 4.8% for 4 years.

CONCLUSIONS: There are significant disparities in trends in prices and consumption of different antineoplastic drugs after the market authorization of a generic or biosimilar. Further analysis is needed to reveal factors responsible for such differences.